These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29207429)

  • 1. [Rheumatoid Arthritis - New Treatment Options].
    Fiehn C
    Dtsch Med Wochenschr; 2017 Dec; 142(24):1844-1848. PubMed ID: 29207429
    [No Abstract]   [Full Text] [Related]  

  • 2. [Rheumatoid polyarthritis: a new treatment].
    Perspect Infirm; 2010; 7(5):46-7. PubMed ID: 21744636
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-interleukin 6: first line in rheumatoid arthritis?
    Marti L; Scheinberg M
    Clin Rheumatol; 2009 Aug; 28(8):877-9. PubMed ID: 19415377
    [No Abstract]   [Full Text] [Related]  

  • 4. Synovial fluid IL-6 concentrations associated with positive response to tocilizumab in an RA patient with failed response to anti-TNF and rituximab.
    Wright HL; Mewar D; Bucknall RC; Edwards SW; Moots RJ
    Rheumatology (Oxford); 2015 Apr; 54(4):743-4. PubMed ID: 25667432
    [No Abstract]   [Full Text] [Related]  

  • 5. Interleukin-6 in rheumatoid arthritis.
    Nishimoto N
    Curr Opin Rheumatol; 2006 May; 18(3):277-81. PubMed ID: 16582692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic agents for rheumatoid arthritis: 2008 and beyond.
    Sweiss NJ; Hushaw LL
    J Infus Nurs; 2009; 32(1 Suppl):S4-17; quiz S19-24. PubMed ID: 19142153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarilumab (Kevzara) for rheumatoid arthritis.
    Med Lett Drugs Ther; 2017 Aug; 59(1527):134-136. PubMed ID: 28787744
    [No Abstract]   [Full Text] [Related]  

  • 8. New therapeutic options in rheumatoid arthritis: a focus on interleukin-6 blockade.
    Furfaro N
    J Infus Nurs; 2011; 34(2):107-15. PubMed ID: 21399456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy.
    Nishina N; Kikuchi J; Hashizume M; Yoshimoto K; Kameda H; Takeuchi T
    Ann Rheum Dis; 2014 May; 73(5):945-7. PubMed ID: 24336338
    [No Abstract]   [Full Text] [Related]  

  • 10. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.
    Woodrick RS; Ruderman EM
    Bull NYU Hosp Jt Dis; 2012; 70(3):195-9. PubMed ID: 23259628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheumatoid arthritis: IL-6 inhibition in RA--déjà vu all over again?
    Ruderman EM
    Nat Rev Rheumatol; 2015 Jun; 11(6):321-2. PubMed ID: 25907702
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial: inflammation, disease-modifying antirheumatic drugs, lipids, and cardiovascular risk in rheumatoid arthritis.
    Liao KP; Solomon DH
    Arthritis Rheumatol; 2015 Feb; 67(2):327-9. PubMed ID: 25331004
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-interleukin-6 therapy in rheumatoid arthritis.
    Woodrick R; Ruderman EM
    Bull NYU Hosp Jt Dis; 2010; 68(3):211-7. PubMed ID: 20969554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond methotrexate monotherapy for early rheumatoid arthritis.
    Scott DL
    Lancet; 2016 Jul; 388(10042):309-310. PubMed ID: 27287831
    [No Abstract]   [Full Text] [Related]  

  • 15. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
    Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanism of action of biological disease--modifying antirheumatic drugs].
    Takahashi N; Ishiguro N
    Nihon Rinsho; 2016 Jun; 74(6):882-6. PubMed ID: 27311173
    [No Abstract]   [Full Text] [Related]  

  • 17. Ups and downs in the treatment strategies of rheumatoid arthritis.
    Schipper LG; van Riel PL
    Rheumatology (Oxford); 2011 May; 50(5):818-20. PubMed ID: 20663813
    [No Abstract]   [Full Text] [Related]  

  • 18. [Rheumatoid arthritis: strategies for biotherapy].
    Nau JY
    Rev Med Suisse; 2012 Oct; 8(358):1988-9. PubMed ID: 23198655
    [No Abstract]   [Full Text] [Related]  

  • 19. Polyarticular late infection of total joint arthroplasties in a patient with rheumatoid arthritis treated with anti-interleukin-6 therapy.
    Wakabayashi H; Takigawa S; Hasegawa M; Kakimoto T; Yoshida K; Sudo A
    Rheumatology (Oxford); 2014 Jun; 53(6):1150-1. PubMed ID: 24273024
    [No Abstract]   [Full Text] [Related]  

  • 20. Interleukin 6 as therapeutic target in athero-/arteriosclerosis--small steps towards a new treatment paradigm in cardiovascular disease?
    Henry RM
    Atherosclerosis; 2011 Dec; 219(2):390-1. PubMed ID: 21840523
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.